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A B S T R A C T
Tuberculosis is a rare cause of acute respiratory distress syndrome (ARDS) and mortality rates are high in tu-
berculosis patients that need treatment with mechanical ventilation. Experience of the use of extracorporeal
membrane oxygenation (ECMO) in such circumstances is scarce. We report the case of an 18 year old man where
prolonged therapy (50 days) with extracorporeal membrane oxygenation (ECMO) allowed extensive lung damage
from miliary tuberculosis to heal. The case reflects how challenging the diagnosis of tuberculosis may be and
how difficult it is to reach adequate blood levels of anti-tuberculosis drugs while on ECMO. It's also an example
of how indications for ECMO have been expanding the last years and that long term ECMO therapy is possible
without serious complications.
1. Introduction
Tuberculosis remains an important global health issue causing
considerable morbidity and mortality. The development of acute re-
spiratory distress syndrome (ARDS) is however rare [1] and most often
seen in disseminated disease (miliary tuberculosis) [2,3]. Mortality rates
for patients with tuberculosis who require mechanical ventilation are
high (60–70%) [3–5], higher than for any other cause of ARDS [1].
Experience with the use of extracorporeal membrane oxygenation (ECMO)
in this setting is limited, with only a handful of case-reports published
[6]. We present a case of miliary tuberculosis where prolonged ECMO
therapy was successful but both diagnosis and treatment of the infec-
tion challenging.
2. Case presentation
A previously healthy 18 year old male was admitted to hospital with
a few days history of fever and shortness of breath. Chest X-ray showed
bilateral interstitial infiltrates and empirical therapy for presumed
community-acquired pneumonia was started. A more thorough history
taking revealed symptoms of weight loss, lethargy and swallowing
difficulties of three months duration. The patient was in hypoxic re-
spiratory failure and therefore intubated within a few hours of
admission. A computed tomography (CT) scan showed widespread nod-
ular infiltrates and signs of an abscess in the mediastinum (Fig. 1). Later
CT scans confirmed leakage of contrast medium from the oesophagus to
the mediastinum but endoscopy did not reveal any obvious pathology.
The patient was septic on admission and needed high-dose vaso-
pressors. Hemodynamic instability resolved within few days but the
respiratory failure did not. The patient received lung-protective me-
chanical ventilation for 18 days, with intermittent prone positioning.
Initial cultures from bronchoalveolar lavage and viral polymerase chain
reaction (PCR) assays were negative. Ziehl-Neelsen staining did not
reveal acid-fast bacilli on repeated samples of tracheal aspirates.
Interferon-ɣ release assay (IGRA) for tuberculosis was indeterminable.
An extensive work-up regarding infectious, malignant and im-
munological causes was negative. Antibiotic therapy was expanded and
the patient received empirical corticosteroids and immunoglobulins. At
last transbronchial biopsies were taken with fiberoptic bronchoscopy
guidance. Shortly after that intervention the patient developed bilateral
tension pneumothoraces, pneumopericardium and subcutant emphy-
sema (Fig. 2). Despite prompt drainage of both pleura, oxygenation of
the patient became critical and veno-venous ECMO therapy was started.
Microscopy of transbronchial biopsies revealed acid-fast bacilli and
tuberculosis treatment was initiated with rifampicin, isoniazide, etham-
butol and pyrazinamide. The diagnosis of miliary tuberculosis was later
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confirmed (26 days after admission) when growth of Mycobacterium
tuberculosis was detected in samples taken at admission. The bacteria
grew in tracheal aspirate, urine and cerebrospinal fluid. Additionally,
granulomas were seen in a bone marrow aspirate, liver and lung
biopsies. The bacteria was found to be susceptible to all first-line anti-
tuberculosis agents. The patient's dysphagia and mediastinal abscess
were probably related to tuberculosis in the mediastinum. During the
ECMO treatment the patient's lungs developed multiple bullae and he
had persistent pneumothoraces where the lungs did not expand despite
patent pleural tubes (Fig. 3).
Serum levels of anti-tuberculosis agents were monitored and levels
of both isoniazid and rifampicin were repeatedly subtherapeutic despite
escalating doses and a change to intravenous administration. After
multiple negative samples, acid-fast bacilli were seen in tracheal aspi-
rates on two occasions, four weeks after the start of treatment. During
the VV-ECMO treatment, a multi-resistant Pseudomonas aeruginosa and
Stenotrophomonas maltophilia were repeatedly cultured from tracheal
aspirates. These bacteria were successfully eradicated with a combi-
nation therapy of inhaled colistin and tobramycin along with intravenous
amikacin, meropenem and ceftazidime/avibactam. As with the anti-tu-
berculosis agents, serum levels of amikacin were low.
After 45 days on ECMO the patient started to show signs of recovery
with increasing lung compliance and re-expansion of the lungs (Fig. 4).
He was successfully weaned from ECMO after 50 days. Complications
during the ECMO run were thrombocytopenia, minor bleedings from
puncture sites and sensory symptoms in lower limbs. The patient stayed
a total of 76 days in the ICU. After three months of rehabilitation he was
back at home and had resumed previous activities, including sports.
3. Discussion
The use of ECMO in ARDS has been increasing rapidly in recent
years [7] and indications may be expanding. We have described suc-
cessful use of ECMO in miliary tuberculosis, even though the patient
had two relative contraindications for ECMO (mechanical ventilation
with a high FiO2 (0.75–1.0) for 18 days and an unknown diagnosis at
the time) [8]. The lack of data on the use of ECMO for tuberculosis
made prognostication difficult. Since the patient was young, without
Fig. 1. A CT scan the day after admission showing multiple nodular infiltrates.
Mediastinal abscess not visible in this slide.
Fig. 2. A CT scan after 18 days in the ICU. The patient developed bilateral
pneumothoraces, pneumopericardium and pneumomediastinum after a trans-
bronchial biopsy. Bilateral pleural tubes in-situ.
Fig. 3. A CT scan after two weeks on VV-ECMO. Both lungs show numerous
bullae and there were persistent bilateral pneumothoraces despite pleural tubes
in-situ.
Fig. 4. A CT scan after 46 days on ECMO. Both lungs have expanded with
functional lung tissue visible again. This correlated with improvement clini-
cally.
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co-morbidities and with a single-organ failure, the therapy was con-
tinued, even though no signs of recovery were discernible for weeks.
Technological advances have made longer ECMO runs possible without
complications and studies have shown equivalent outcome for patients
with short and extended runs [9].
Tuberculosis is a rare cause of ARDS, even in high burden regions
[2,10]. ARDS is most often seen in the disseminated form of the disease
(miliary) [2,3] which only 1–2% of all tuberculosis patients exhibit
[11,12]. Published case-series of miliary tuberculosis have shown that
3–10% of these patients develop ARDS [11,13]. The clinical picture
tends to be with prodromal symptoms (fever, anorexia) for weeks prior
to a rapid deterioration [2,3] and this might help to differentiate ARDS
from tuberculosis from other causes of ARDS.
The diagnosis of miliary tuberculosis can be challenging when the
infection has caused the development of ARDS. The classical miliary
pattern may be absent on a chest X-ray in 50% of patients [12] although
computed tomography scans have a higher sensitivity. Waiting for po-
sitive cultures (2–6 weeks) is not practical in these critically ill patients.
Rates of positive microscopy for acid-fast bacilli in sputum samples
have been low (32%–36%) in case series of miliary tuberculosis
[11,13]. The yield of microscopy was similar on samples obtained with
the aid of bronchoscopy (31%) but the diagnosis of tuberculosis was
rapidly obtained in 79% of patients with the addition of transbronchial
biopsies during bronchoscopy [14]. Current guidelines recommend fi-
beroptic bronchoscopy in sputum negative patients with suspected
miliary tuberculosis, and that sampling should include bronchial
brushings and/or transbronchial biopsy, especially in critically ill pa-
tients [15]. Newer molecular methods (PCR) on bronchoalveolar lavage
have shown 60–80% sensitivity for tuberculosis in smear-negative pa-
tients [16,17] and may be an alternative to transbronchial biopsies
where available. Transbronchial biopsies are not without risks in this
patient population as demonstrated in our case.
Successful eradication of tuberculosis is dependent on adequate
blood levels of anti-tuberculosis drugs [1]. The first-line agents (apart
from rifampicin) are generally only available as oral preparations and
thus dependent on adequate absorption from the gastrointestinal tract,
which cannot be relied on in the critically ill. We did not reach ther-
apeutic targets for two agents during the ECMO therapy. Sub-
therapeutic levels of these drugs while on ECMO have been reported
before [18]. The ECMO circuit increases the volume of distribution for
drugs and there is evidence for substantial sequestration of drugs in the
circuits [19]. There is a general lack of guidelines on optimal drug
dosing for patients on ECMO.
The development of pneumothorax is not uncommon in tuberculosis
and the management of this during ECMO can be challenging, as
pleural tube placement is frequently accompanied by bleeding. Current
guidelines [8] from the Extracorporeal Life Support Organization
(ELSO) recommend drainage with continuous suction for symptomatic
pneumothorax (> 50% of hemithorax, enlarging or with hemodynamic
compromise). Inspiratory pressure on the ventilator should be kept low
or even at zero until air leaks have sealed. Managing patients with
ARDS on ECMO without a ventilator is an emerging approach [20,21]
that may be useful in cases like this but further studies are needed.
4. Conclusions
We have reported a case where prolonged ECMO therapy allowed
extensive lung injury from miliary tuberculosis to heal, with a good
outcome for the patient. Both diagnosis and treatment of tuberculosis is
complex in the intensive care setting.
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